Trump Administration Proposes 100% Tariffs on Imported Pharmaceuticals

The Trump administration is reportedly preparing to impose 100% tariffs on patented drugs from companies that have not agreed to lower U.S. drug prices. The proposal, part of an ongoing trade strategy, could impact major pharmaceutical firms and reshape the drug pricing landscape.

• The Trump administration is considering 100% tariffs on patented drugs from companies that have not agreed to lower U.S. prices.
• Companies that move manufacturing to the U.S. or negotiate price-cutting deals may qualify for reduced or no tariffs.
• Over a dozen major drugmakers, including Eli Lilly, Pfizer, and Novo Nordisk, have signed agreements to lower drug prices and are exempt from tariffs for three years.
• A 20% tariff is proposed for companies onshoring production, increasing to 100% after four years.
• Separate tariff rates are being developed for the EU, Japan, South Korea, Switzerland, and the U.K. based on bilateral agreements.
• Generic drugs would face no additional tariffs under the proposal.